Introduction {#s01}
============

A single membrane-bound organelle, peroxisome, catalyzes essential catabolic and anabolic reactions such as detoxification of hydrogen peroxide, β-oxidation of very long chain fatty acids, and the synthesis of ether phospholipids ([@bib65]). Recent advances including identification of several *PEX* genes have revealed that peroxisomal homeostasis involving regulation of the number, morphology, and metabolic functions of peroxisomes is maintained by coordinating biogenesis, proliferation, division, and degradation of peroxisomes ([@bib20]). In addition, intracellular movement of peroxisomes is observed in many organisms and is thought to contribute to inheritance, spatial distribution, and functions of peroxisomes ([@bib33]; [@bib43]).

Intracellular organelles are transported by molecular motors along the cytoskeletons of microtubular networks or actin filaments, which requires a highly specific organelle--motor relationship via direct or adapter protein--mediated interactions ([@bib26]; [@bib31]). In *Saccharomyces cerevisiae*, a peroxisomal membrane protein (PMP), Inp2, interacts with the type V myosin motor Myo2 to transport peroxisomes along actin cables to the bud ([@bib14], [@bib15]). In mammalian cells, peroxisomes show two types of motility: one for relatively slow oscillation observed in the majority and the other for fast directional long-distance movement in a microtubule-dependent manner as for the transport of other organelles in mammals ([@bib51]; [@bib67]; [@bib56]; [@bib5]; [@bib16]). The long-range movement of peroxisomes is shown to require a PMP, Pex14p, that directly binds to tubulin ([@bib5]). Furthermore, involvement of the microtubule-dependent motors KifC3 ([@bib13]) and dynein ([@bib56]) in peroxisomal movement are suggested in mammalian cells. These observations implicate a linkage between peroxisomes and microtubule-associated molecular motors. However, molecular mechanisms underlying intracellular transport of peroxisomes in mammals remain largely undefined mainly because of a lack of peroxisomal adapter protein or proteins linking peroxisomes to an unknown specific motor complex.

The molecular basis of mitochondrial transport is better elucidated. Mitochondrial Rho GTPase (Miro) proteins localized to mitochondrial outer membrane (MOM) belong to a family of tail-anchored (TA) membrane proteins ([@bib55]; [@bib6]; [@bib57]; [@bib59]). Two Miro family members, Miro1 and Miro2, are identified in mammalian cells ([@bib17]). Recent studies revealed that mammalian Miro proteins interact with the adapter proteins TRAK1 and TRAK2, which recruit microtubule-associated molecular motors in the transport of mitochondria ([@bib22]; [@bib66]). Miro1-mediated mitochondrial transport is regulated by cytosolic calcium ion concentration ([@bib54]; [@bib37]; [@bib66]; [@bib10]) and its GTPase activity ([@bib36]; [@bib3]).

Targeting of PMPs to peroxisomes requires the peroxisomal membrane-targeting signal (mPTS) and its cytosolic receptor Pex19p ([@bib30]; [@bib39]). Like most PMPs ([@bib30]; [@bib23]; [@bib39]; [@bib38]; [@bib11]; [@bib35]), a mammalian peroxisomal TA protein, Pex26p, is posttranslationally targeted from the cytosol to peroxisomes via the Pex19p- and Pex3p-dependent class I pathway ([@bib68]). The C-terminal region of Pex26p, containing a transmembrane domain (TMD) with relatively low hydrophobicity and a following short cluster of basic amino acids, allows specific recognition by Pex19p and escape from capture by TRC40 ([@bib68]), the import receptor of ER-destined TA proteins in the guided entry of the TA protein pathway ([@bib25]). TA proteins localized to MOM appear to be transported by the unassisted pathway ([@bib8]; [@bib58]; [@bib32]). Moreover, a part of TA proteins targets multiple organelles, conferring more complexity in TA protein import ([@bib7]; [@bib50]). The mechanisms underlying such selective localization of TA proteins are not fully elucidated. Most recently, analysis of subcellular localization for human TA proteins suggested a subset of TA proteins including Miro proteins dually localized to peroxisomes and mitochondria ([@bib12]).

In this study, we identified three splicing variants of Miro1 termed Miro1-var2, Miro1-var3, and Miro1-var4 in human cells. Miro1-var2 and Miro1-var4 were partially and mostly localized to peroxisomes, respectively, and both are involved in microtubule-dependent long-range movement of peroxisomes.

Results {#s02}
=======

Identification of three distinct splicing variants of Miro1 {#s03}
-----------------------------------------------------------

In RT-PCR for cloning of human *Miro* cDNAs, we identified three distinct splicing variants of Miro1, named Miro1-var2, -var3, and -var4, in addition to authentic well-characterized Miro1 (hereafter termed Miro1-var1) and Miro2, C-TA--type MOM proteins ([Fig. 1 A](#fig1){ref-type="fig"}). Compared with 618-aa Miro1-var1, Miro1-var2 and Miro1-var3 contained 32 and 41 aa insertions, termed insertions 1 and 2, respectively ([Fig. 1 A](#fig1){ref-type="fig"}, pink and orange), and Miro1-var4 contained both insertions. These insertions were located between the second GTPase domain and the TMD of Miro1-var1 ([Fig. 1 A](#fig1){ref-type="fig"}). Genomic information of the DNA database indicated that insertions 1 and 2 of Miro1 variants were encoded by the alternatively spliced putative 19th and 20th exons of human *Miro1* gene, respectively ([Figs. 1 A](#fig1){ref-type="fig"} and S1 A). Similar genome structure and splicing variants of Miro1 were also found in mice (Fig. S1 B). Semiquantitative RT-PCR to amplify the alternative splicing region of *Miro1* variants ([Fig. 1 A](#fig1){ref-type="fig"}) showed that mRNA of each splicing variant of *Miro1* was expressed at varying levels in HeLa cells ([Fig. 1 B](#fig1){ref-type="fig"}). Compared with predominantly expressed *Miro1-var1* and *Miro1-var2*, *Miro1-var3* and *Miro1-var4* were expressed at ∼10% and a lesser levels, respectively, of *Miro1-var1* and *Miro1-var2* ([Fig. 1 B](#fig1){ref-type="fig"}). A similar expression profile of *Miro1* variant mRNAs was found in HEK cells (Fig. S1 C) and various mouse tissues except for testis, where Miro1-var4 mRNA was highly expressed (unpublished data). A search for genome DNA database showed that both insertions 1 and 2 are conserved in *Miro1* genes in mammals; only the insertion 2 is found in other vertebrates such as *Gallus gallus* (chicken) and *Xenopus tropicalis* (frog; Fig. S1 D). These results suggested that the splicing variants of *Miro1* with the unique insertions are specifically expressed in mammals.

![**Distinct intracellular localization of splicing variants of Miro1. (A)** Domain structure of human authentic Miro1 and three splicing variants of Miro1. EF hands, calcium-binding EF hand domains. Partial genome structure of the human *MIRO1* gene encoding the C-terminal region of Miro1 variants is shown at the bottom. Pink and orange boxes indicate the insertions 1 and 2 generated by alternative splicing of exons 19 and 20, respectively. Primers for RT-PCR are shown by half-arrowheads at the top. **(B)** Expression of mRNA of *MIRO1* splicing variants in HeLa cells. Human *MIRO1* encoding the C-terminal variable region of Miro1 was amplified by semiquantitative RT-PCR with RNA from HeLa cells and a pair of primers shown in A. Size markers are shown on the left. **(C)** Intracellular localization of splicing variants of Miro1. HA~2~-Miro1 variants were assessed by transient expression in HeLa cells for 24 h and immunostaining with antibodies to HA (a, e, i, and m; green), Pex14p (b, f, j, and n; red), and Tom20 (c, g, k, and o; blue). Merged images are shown (d, h, l, and p), and the boxed areas were magnified 3.5-fold in insets. Representative images are shown. Bars: (main images) 10 µm; (insets) 2 µm. **(D)** Data in C were quantified for localization of respective Miro1 variants to mitochondria (Mt; white), peroxisomes (Ps; dark gray), and both (Mt+Ps; light gray). Data are shown as means ± SD. Transfected cells (*n* ≥ 100) for each condition were counted in three independent experiments.](JCB_201708122_Fig1){#fig1}

Miro1-var2 and Miro1-var4 localize to peroxisomes {#s04}
-------------------------------------------------

We investigated intracellular localization of the splicing variants of Miro1. N-terminally tandem HA--tagged splicing variants of Miro1 (HA~2~-Miro1 variants) were expressed in HeLa cells at a lower expression levels by transfecting 1/10 of the amount of plasmids used for typical transfection assays to avoid mislocalization by incorrect targeting. HA~2~--Miro1-var3 was entirely coincided with a MOM protein Tom20 ([Fig. 1 C](#fig1){ref-type="fig"}, i--k; and [Fig. 1 D](#fig1){ref-type="fig"}), indicating that its mitochondrial localization is like an authentic Miro1 variant, HA~2~-Miro1-var1 ([Fig. 1 C](#fig1){ref-type="fig"}, a--d; and [Fig. 1 D](#fig1){ref-type="fig"}; [@bib17]). Notably, in ∼75% of the cells expressing the longest HA~2~--Miro1-var4, Miro1-var4 was localized to Pex14p-positive particle structures, peroxisomes, whereas in the remaining 25% of cells, it was discernible in mitochondria and peroxisomes ([Fig. 1 C](#fig1){ref-type="fig"}, m--p; and [Fig. 1 D](#fig1){ref-type="fig"}). HA~2~--Miro1-var4 localizing to peroxisomes showed no significant effect on mitochondrial morphology ([Fig. 1 C](#fig1){ref-type="fig"}, o). Localization of HA~2~--Miro1-var2 was classified into two types: ∼60% was found in both mitochondria and peroxisomes, and the rest was exclusively in mitochondria ([Fig. 1 C](#fig1){ref-type="fig"}, e--h; and [Fig. 1 D](#fig1){ref-type="fig"}). Similar peroxisomal localization patterns were observed in the FLAG-EGFP--tagged C-terminal regions of Miro1 (termed MVC) encompassing the TMD and the respective insertions of Miro1-var4 and Miro1-var2, named FL-EGFP-MV4C and MV2C, respectively (Fig. S2, A--C). FL-EGFP-MV3C was detected only in mitochondria, as was FL-EGFP-MV1C (Fig. S2, A--C), consistent with an earlier study ([@bib18]). These results strongly suggest that Miro1-var4 and Miro1-var2 are mainly and partially localized to peroxisomes, respectively, in a manner dependent on the insertion 1.

Miro1 variants localize to peroxisomes as a TA membrane protein {#s05}
---------------------------------------------------------------

To further investigate peroxisomal localization of Miro1 variants, we raised a rabbit polyclonal antibody against a 32-aa peptide corresponding with the insertion 1, named anti--Miro1-ins1 antibody. In immunoblot analysis, this antibody specifically recognized human Miro1-var2 and Miro1-var4, which were expressed in CHO cells ([Fig. 2 A](#fig2){ref-type="fig"}, top, lanes 5 and 6). The antibody was not cross-reactive to the other Miro1 variants and Miro2 ([Fig. 2 A](#fig2){ref-type="fig"}, top, lanes 2--4). We used another type of anti-Miro1 antibody, termed the anti-Miro1/2 antibody, reactive to all of the four Miro1 variants and Miro2 ([Fig. 2 A](#fig2){ref-type="fig"}, bottom, lanes 1--6). In subcellular fractionations of the postnuclear supernatant (PNS) fraction of HEK cells, several contiguous bands were detected by anti-Miro1/2 antibodies ([Fig. 2 B](#fig2){ref-type="fig"}), which were suspected to be three Miro1 variants other than Miro1-var4, and Miro2 was detected by mRNA expression level of Miro1 variants (Fig. S1 C) and their mobility ([Fig. 2 A](#fig2){ref-type="fig"}, bottom). These bands showed a distribution pattern similar to that of the MOM protein Tom20, hence suggesting that Miro1-var1, Miro1-var2, Miro1-var3, and Miro2 are located on mitochondria ([Fig. 2 B](#fig2){ref-type="fig"}).

![**Peroxisomal localization of endogenous Miro1 variants. (A)** To verify two types antibodies raised to Miro1 and migration of Miro variants in SDS-PAGE, lysates of CHO-K1 cells transfected with nontagged *Miro2* (lane 2), *Miro1* variants (lanes 3--6), and a mock plasmid (lane 1) were analyzed by immunoblotting. Note that anti--Miro1-ins1 antibody specifically recognizes Miro1-var2 and Miro1-var4 (lanes 5 and 6), whereas anti-Miro1/2 antibody detects all of the Miro1 variants and Miro2 (lanes 2--6). Fraction 2 (lane 7) and half and one-eighth aliquots of fractions 10 and 11, respectively (lanes 8 and 9), from subcellular fractions of HEK cells in B were similarly analyzed. **(B)** Subcellular fractionation of HEK cells. PNS fraction of HEK cells was fractionated in iodixanol density gradient as described in the Subcellular fractionation section of Materials and methods. Equal-volume aliquots of the collected fractions were analyzed by SDS-PAGE and immunoblotting with antibodies indicated on the left. Cytochrome P450 reductase (P450R), Tom20, and Pex3p are markers for ER, mitochondria (Mito), and peroxisomes (Peroxi), respectively. Arrowheads indicate fractions of highly purified peroxisomes. White lines indicate intervening lanes have been spliced out. **(C)** Peroxisomal Miro1-var2 is an integral membrane protein. PNS fraction of HEK cells was centrifuged at 3,000 *g*, and the supernatant (S; 3K*g* sup) fraction was divided into three aliquots. One aliquot was directly lysed in Laemmli sample buffer (input). The other two were separately treated with 1 M NaCl and 0.1 M Na~2~CO~3~, respectively, and separated into supernatant and pellet (P) fractions. Equal aliquots of respective 3K*g* sup fractions and a PNS fraction were analyzed by SDS-PAGE and immunoblotting with antibodies specific for the insertion 1 of Miro1, Tom20, the PMPs Pex14p and Pex13p, and acyl-CoA oxidase (AOx), a peroxisomal matrix enzyme. Only the B chain of AOx that is produced by intraperoxisomal processing of full-length AOx is shown. **(D)** TMD of Miro1-var2 and Miro1-var4 is required for their localization to peroxisomes. HeLa cells transiently transfected with *HA~2~--Miro1-var2ΔTMD* (a and b) and *HA~2~--Miro1-var4ΔTMD* (c and d) were immunostained with antibodies to HA and Pex14p as in [Fig. 1 C](#fig1){ref-type="fig"}. Bars, 10 µm. **(E)** Membrane topology of endogenous Miro1-var2 in peroxisomes. The 3K*g* sup fraction of HEK cells was incubated for 30 min on ice in the absence (lane 1) or presence of 100 µg/ml trypsin alone (lane 2) and both trypsin and 0.1% Triton X-100 (lane 3). Equal aliquots were analyzed by SDS-PAGE and immunoblotting with indicated antibodies, including the anti-Pex14p antibody specific for the cytosolically faced C-terminal part of Pex14p. **(F)** Schematic diagram of the topology of Miro1-var2 and Miro1-var4 in peroxisomes. Dark gray boxes, insertions 1 and 2; black and light gray ellipses, a TMD and two GTPase domains, respectively.](JCB_201708122_Fig2){#fig2}

Notably, a portion of proteins recognized by anti--Miro1-ins1 antibody was found in heavier fractions up to fraction 2, where PMP Pex3p was enriched ([Fig. 2 B](#fig2){ref-type="fig"}), whereas the proteins were mostly present in mitochondrial fractions. The band detected by anti--Miro1-ins1 antibody in fraction 2 as well as fractions 10 and 11 showed the mobility identical to Miro1-var2 ([Fig. 2 A](#fig2){ref-type="fig"}, lanes 5 and 7--9). Collectively, these results indicated that at least endogenous Miro1-var2 is partially localized in peroxisomes in HEK cells, consistent with immunostaining of HA~2~--Miro1-var2 ([Fig. 1 C](#fig1){ref-type="fig"}, e--h). Although Miro1-var4 was possibly present in peroxisomes, endogenous Miro1-var4 was below the detectable level even in peroxisome-enriched fractions in HEK cells, presumably because of much lower expression of the mRNA (Fig. S1 C) and inefficient recognition by anti--Miro1-ins1 antibody ([Fig. 2 A](#fig2){ref-type="fig"}, compare lanes 5 and 6).

Next, membrane topology of peroxisome-localized Miro1 variants was assessed. In a post-heavy mitochondria fraction enriched in peroxisomes and almost devoid of mitochondria, endogenous Miro1-var2 was resistant to high-salt washing and alkaline extraction, indicative of an integral membrane protein as for typical PMPs such as Pex14p and Pex13p ([Fig. 2 C](#fig2){ref-type="fig"}). Consistent with this result, truncated mutants of HA~2~--Miro1-var4 and HA~2~--Miro1-var2 lacking their C-terminal TMD were diffused in the cytosol ([Fig. 2 D](#fig2){ref-type="fig"}), hence indicating that TMD is essential for their peroxisomal localization, similar to mitochondrial anchoring of Miro1-var1 ([@bib18]). The region including insertion 1 of Miro1-var2 was sensitive to trypsin digestion in the absence of detergent Triton X-100, showing that the N-terminal region was faced to cytosol exactly as the C-terminal region of Pex14p was ([Fig. 2 E](#fig2){ref-type="fig"}; [@bib60]). Furthermore, immunostaining of HeLa cells semipermeabilized with digitonin demonstrated that the N-terminal part of HA~2~--Miro1-var4 and HA~2~--Miro1-var2 were exposed to the cytosol (Fig. S2 D). Collectively, we concluded that Miro1-var2 and presumably Miro1-var4 are localized to peroxisomes as a TA membrane protein with the same topology as mitochondrial Miro1-var1 ([Fig. 2 F](#fig2){ref-type="fig"}). Miro1-var4 was mainly used for further studies.

Peroxisomal localization of Miro1-var4 and Miro1-var2 is dependent on its insertion 1-- and Pex19p-mediated PMP import pathway {#s06}
------------------------------------------------------------------------------------------------------------------------------

Pex19p recognizes peroxisomal TA proteins such as Pex26p via mPTS-containing C-terminal regions ([@bib24]; [@bib68]). To investigate whether Pex19p is involved in peroxisomal import of Miro1-var4 and Miro1-var2, Miro1 variants were examined for binding to Pex19p. In the cell-free immunoprecipitation assay using proteins synthesized in a rabbit reticulocyte lysate (RRL) translation system, the C-terminal regions of Miro1-var4 and Miro1-var2 but not Miro1-var1 and Miro1-var3 interacted with HA~2~-Pex19p to a lesser extent than that of Pex26p ([Fig. 3 A](#fig3){ref-type="fig"}). This was well correlated with the insertion 1--dependent peroxisomal localization of Miro1-var4 and Miro1-var2 ([Figs. 1 B](#fig1){ref-type="fig"} and S2 B), suggesting a potential Pex19p binding site in the insertion 1. Indeed, we found amino acid sequences at the C-terminal parts of insertion 1 and adjacent linker regions in Miro1-var4 and Miro1-var2 that were similar to typical Pex19p-binding sites, including the core 9-aa sequences each identified in Pex13p and Pex11p of *S. cerevisiae* and human adrenoleukodystrophy protein ([Fig. 3 B](#fig3){ref-type="fig"}; [@bib52]; [@bib23]). Therefore, leucine 608, one of the highly conserved residues in the insertion 1 was substituted to proline in FL-EGFP-MVC variants of Miro1-var4 and Miro1-var2, corresponding with the mutations L207P in *Sc*Pex13p and L35P in *Sc*Pex11p, both defective in interaction with Pex19p ([@bib52]). L608P mutation abrogated the interaction of Miro1-var4 and Miro1-var2 with Pex19p in vitro ([Fig. 3 C](#fig3){ref-type="fig"}), leading to mislocalization of Miro1-var4 and Miro1-var2 to mitochondria ([Fig. 3 D](#fig3){ref-type="fig"}). Furthermore, overexpressed WT FL-EGFP-MV4C and FL-EGFP-MV2C, but not those with L608P mutation, were partly stabilized in the cytosol upon coexpression of Pex19p (Fig. S3 A) as shown in several PMPs including Pex26p ([@bib53]; [@bib30]; [@bib68]; [@bib35]). L608P mutation likewise interfered with peroxisomal localization of full-length Miro1-var4 (Fig. S3 C, a--d) and Miro1-var2 (e--h). These results further supported that C-terminal region of the insertion 1 is a primary Pex19p binding site. Basic amino acid residues in the hydrophilic luminal region were shown to be also important for peroxisomal targeting of TA proteins ([@bib68]). Replacement of the two basic amino acids located within putative luminal regions of Miro1-var4 and Miro1-var2 by serine residues (named KR2S; [Fig. 3 B](#fig3){ref-type="fig"}) markedly lowered the efficiency of their peroxisomal localization, resulting in mislocalization predominantly to mitochondria (Fig. S3 B). These results show that both insertion 1 and the basic charge in luminal region are essential for the efficient localization of Miro1-var4 and Miro1-var2 to peroxisomes. Tandem positioning of the insertions 1 and 2 potentially elevated the targeting efficiency of Miro1-var4 to peroxisomes.

![**Miro1-var2 and Miro1-var4 are translocated to peroxisomes in a manner dependent on their specific insertion 1 and the PMP receptor Pex19p. (A)** FLAG-EGFP--fused C-terminal regions of Miro1 variants (FL-EGFP-MVCs) indicated at the top were synthesized in RRL in the presence of RRL-synthesized HA~2~-Pex19p and subjected to immunoprecipitation (IP) with anti-FLAG agarose beads. Immunoprecipitates and input (10%) were analyzed by immunoblotting using antibodies to HA and FLAG. Solid and open arrowheads indicate unmodified and farnesylated HA~2~-Pex19p, respectively. **(B)** Partial amino acid sequences near the C terminus of insertion 1 of human Miro1-var2 and Miro1-var4 are aligned with those of known Pex19p binding sites such as those of *S. cerevisiae* Pex13p and Pex11p and human adrenoleukodystrophy protein (ALDP). Underlined and bold letters indicate experimentally identified Pex19p binding sites and the core 9-aa residues in typical Pex19p-binding sites in three representative PMPs ([@bib52]; [@bib23]) and putative corresponding ones in human Miro1 variants, respectively. The dashed line shows the C terminus of insertion 1. Asterisks and blue letters show highly conserved amino acid residues of putative Pex19p binding sites and leucine^608^, respectively, in Miro1-var2 and Miro1-var4. An amino acid sequence of the C-terminal region of Miro1-var2 and Miro1-var4 containing a TMD (shaded) and two lysine and arginine residues mutated in KR2S mutants (colored in red) are also shown. **(C)** FL-EGFP-MVC variants and their L608P mutants were synthesized in RRL in the presence of HA~2~-Pex19p and immunoprecipitated with anti-FLAG agarose beads as in A. Solid and open arrowheads indicate unmodified and farnesylated HA~2~-Pex19p, respectively. **(D)** L608P mutation in insertion 1 impairs peroxisomal localization of Miro1-var2 and Miro1-var4. HeLa cells were transiently transfected with *FLAG-EGFP-MV4C-L608P* (a--d) and *FLAG-EGFP-MV2C-L608P* (e--h) and immunostained using antibodies to Pex14p (b and f, red) and Tom20 (c and g, blue) as in [Fig. 1 C](#fig1){ref-type="fig"}. EGFP fluorescence of FL-EGFP-MVCs (a and e, green) and merged views (d and h) are shown. **(E)** In vitro import assay of Miro1 variants was performed by incubating semipermeabilized HeLa cells at 26°C for 1 h with cytosolic fractions each containing FLAG-Pex19p plus HA~2~--Miro1-var4 (a and b), HA~2~--Miro1-var2 (c and d), or HA~2~-Pex26p (e and f). Cells were immunostained with antibodies against HA and Pex14p. Bars, 10 µm. **(F)** Cells shown in E were treated with 0.1 M Na~2~CO~3~ and separated into soluble (supernatant, S) and membrane (pellet, P) fractions. Equal aliquots of respective fractions were analyzed by immunoblotting with the indicated antibodies.](JCB_201708122_Fig3){#fig3}

Next, we performed peroxisomal import of Miro1-var4 and Miro1-var2 by an in vitro PMP import assay system using semiintact cells ([@bib38]; [@bib68]; [@bib35]). When cytosolic fractions prepared from the cells coexpressing HA~2~--Miro1-var4 or HA~2~--Miro1-var2 with FLAG-Pex19p were incubated with semiintact HeLa cells, both HA~2~-Miro1 variants were detected exclusively in Pex14p-positive particles, peroxisomes ([Fig. 3 E](#fig3){ref-type="fig"}, a--d), with lower efficiency than HA~2~-Pex26p (e and f). Miro1-var4 and Miro1-var2 targeted to peroxisomes were mostly integrated into the peroxisomal membrane as assessed by resistance to the alkaline extraction ([Fig. 3 F](#fig3){ref-type="fig"}). Collectively, these results strongly suggest that Pex19p interacts with Miro1-var4 and Miro1-var2 via their insertion 1 and delivers them to peroxisomes.

Miro1-var4 promotes microtubule-dependent accumulation of peroxisomes at cell periphery {#s07}
---------------------------------------------------------------------------------------

Miro1-var1 mediates intracellular transport of mitochondria as a mitochondrial receptor by forming a microtubule-dependent transport complex in which its GTPase activity is important ([@bib36]; [@bib3]). By analogy to mitochondrial Miro1-var1, we investigated whether peroxisomal Miro1 variants are involved in intracellular transport of peroxisomes. Notably, expression of HA~2~--Miro1-var4 in HeLa cells often induced accumulation of peroxisomes, but not mitochondria, at the cell periphery ([Fig. 4 A](#fig4){ref-type="fig"}, arrowheads). About 60% of the cells expressing WT Miro1-var4 showed such accumulation of peroxisomes at the cell periphery ([Fig. 4 B](#fig4){ref-type="fig"}, a--c; and [Fig. 4 C](#fig4){ref-type="fig"}). Two GTPase-1 mutants of Miro1-var1, a constitutively active P13V mimicking its GTP-bound form and a dominant-negative T18N defective in GTP binding, exhibit similar and much fewer activities, respectively, as compared with WT in mitochondrial transport ([@bib36]). An analysis using the corresponding GTPase-1 mutant of Miro1-var4, Miro1-var4--P13V, yielded clustered peroxisomes with efficiency similar to WT Miro1-var4, whereas Miro1-var4--T18N exhibited much fewer numbers of the accumulated peroxisomes ([Fig. 4 C](#fig4){ref-type="fig"}). However, peroxisomal accumulation at the cell periphery was hardly observed in cells expressing WT Miro1-var1 and its mutants P13V and T18N ([Fig. 4 C](#fig4){ref-type="fig"}). Importantly, accumulation of peroxisomes induced by a lower-level expression of Miro1-var4 was completely abolished by treatment of nocodazole, a microtubule-depolymerizing agent ([Fig. 4 B](#fig4){ref-type="fig"}, d--f; and [Fig. 4 C](#fig4){ref-type="fig"}). These results suggest that Miro1-var4 is specifically involved in the peroxisomal transport toward plus ends of the microtubule network in a manner dependent on its GTPase activity and microtubules.

![**Miro1-var4 induces accumulation of peroxisomes in the cell periphery. (A)** HeLa cells expressing HA~2~--Miro1-var4 were immunostained with antibodies to HA (a, green), Pex14p (b, red), and Tom20 (c, blue) as in [Fig. 1 C](#fig1){ref-type="fig"}. The merged image (d) and 3.5-fold magnified views of the boxed areas (insets) were shown. Note that HA~2~--Miro1-var4 was often colocalized with Pex14p-positive accumulates of peroxisomes in the cell periphery (arrowheads). **(B)** Nocodazole treatment abrogates Miro1-var4--induced accumulation of peroxisomes at the cell periphery. HeLa cells expressing HA~2~--Miro1-var4 as in A were treated with DMSO (vehicle; a--c) or 20 µM nocodazole for 1 h (d--f) and immunostained with antibodies to HA, Pex14p, and α-tubulin. Circles indicate peroxisome-enriched regions in cell periphery. Representative images are shown. Bars: (main images) 10 µm; (insets) 2 µm. **(C)** HeLa cells transfected with an empty vector (mock) or WT and respective GTPase mutants, P13V and T18N of *HA~2~--Miro1-var4* and *HA~2~--Miro1-var1* were treated with DMSO (−) or nocodazole (+) and immunostained as in B. Percentages of cells exhibiting normal distribution of peroxisomes throughout the cytoplasm (normal, open bar) and accumulation of peroxisomes in the cell periphery (accumulated, solid bar) were represented as the means. Transfected cells (*n* ≥ 100) for each condition repeated three times.](JCB_201708122_Fig4){#fig4}

Peroxisomal Miro1 variants are involved in intracellular movement of peroxisomes {#s08}
--------------------------------------------------------------------------------

Given that Miro1-var1 regulates mitochondrial transport ([@bib55]; [@bib6]; [@bib57]; [@bib59]) and Miro1-var4 is involved in intracellular transport of peroxisomes ([Fig. 4](#fig4){ref-type="fig"}), it is particularly of interest and importance to investigate peroxisomal movement in living cells. We used HeLa cells stably expressing peroxisome-targeted EGFP (EGFP fused with a tripeptide consisting of Ser-Lys-Leu at its C terminus; EGFP-SKL), named HeLa/EGFP-SKL, to acquire time-lapse images of peroxisomal motility ([Fig. 5 A](#fig5){ref-type="fig"}). In this experiment, the directional movement frequency (DMF) of peroxisomes was defined as a rate of a directional movement of peroxisomes that were \>0.5 µm/s in velocity and \>2 µm in distance in total peroxisomes for 5-min measurements. Under normal conditions, ∼10% of total peroxisomes moved fast and directionally in HeLa/EGFP-SKL cells ([Fig. 5, A and B](#fig5){ref-type="fig"}; and Video 1) and likewise in CV1 cells ([@bib67]). Transient expression of mCherry-tagged WT Miro1-var4 increased DMF by 2.5-fold ([Fig. 5 B](#fig5){ref-type="fig"} and Video 2), whereas GTPase-inactive mCherry--Miro1-var4--T18N gave rise to a marked decrease of DMF, indicative of its dominant-negative effect ([Fig. 5 B](#fig5){ref-type="fig"}). Tagging of mCherry to Miro1 variants showed no effects on their localization, as assessed by immunostaining (Fig. S4 A). Nocodazole treatment almost completely abrogated DMF in normal cells ([Fig. 5 C](#fig5){ref-type="fig"}), suggesting that directional movement of peroxisomes was regulated in a manner dependent on microtubule and GTPase activity of Miro-var4. The peroxisome movement represented by DMF was consistent with the accumulation of peroxisomes at cell peripheries ([Fig. 4](#fig4){ref-type="fig"}).

![**Miro1-var2 and Miro1-var4 are specifically involved in fast directional movement of peroxisomes in a manner dependent on its GTPase activity and microtubules. (A)** Live imaging of peroxisome movement. Time-lapse images of peroxisomes in HeLa cells stably expressing EGFP-SKL (HeLa/EGFP-SKL) were acquired by confocal fluorescence microscopy at one picture per second. Arrowheads (yellow) indicate a peroxisome showing fast and long-distance movement. Bars, 5 µm. **(B)** HeLa/EGFP-SKL cells were transfected with an empty vector (mock), *mCherry--Miro1-var4--WT* (WT), or *T18N* (T18N) encoding a dominant-negative mutant of the first GTPase domain. At 24 h after transfection, DMF of peroxisomes in mCherry-positive cells was quantified as described in the Live imaging of peroxisomes section of Materials and methods. \*, P \< 0.05 versus mock-treated cells (Student's *t* test). **(C)** HeLa/EGFP-SKL cells expressing WT mCherry--Miro1-var4 were treated for 1 h with DMSO (vehicle) or 20 µM nocodazole as in [Fig. 4 B](#fig4){ref-type="fig"}. DMF of peroxisomes was analyzed as in B. \*\*, P \< 0.01 versus vehicle-treated cells (Student's *t* test). **(D)** Expression of mCherry-Miro1 variants. HeLa/EGFP-SKL cells were treated for 72 h with control siRNA (lane 1) or *Miro1* siRNA against all of the Miro1 variants (lanes 2--6). Cells were then transfected with an empty vector (mock, lanes 1 and 2) or plasmids encoding an siRNA-resistant version of mCherry-Miro1 variants (mCherry-Miro1 rescue variants, lanes 3--6) as indicated at the top. After further 24-h culture, cells were lysed and analyzed by SDS-PAGE and immunoblotting with anti--Miro1-ins1 antibody (top) and anti-RFP antibody (bottom). The arrowhead indicates endogenous Miro1-var2. **(E)** HeLa/EGFP-SKL cells were transfected with *Miro1* siRNA and plasmids encoding mCherry-Miro1 rescue variants as in D. At 24 h after transfection of plasmids, DMF of peroxisomes was analyzed as in B. Data are shown as means ± SD (error bars). Cells (*n* ≥ 6) for each condition in three independent experiments. \*, P \< 0.05 (one-way ANOVA followed by a Dunnett's test). **(F)** Accumulation of peroxisomes at the cell periphery requires Pex14p and Miro1-var4. Normal fibroblasts (a--d) and fibroblasts from a *PEX14*-deficient patient (PBD-K01; e--h) were cotransfected with *EGFP-PEX26* and *HA~2~--Miro1-var4* for 48 h and immunostained with antibodies to HA (b and f; red) and Pex14p (c and g; blue). EGFP fluorescence of EGFP-Pex26p (a and e; green) and merged views (d and h) are shown. Arrowheads indicate accumulated peroxisomes in the cell periphery (a--d). Representative images are shown. Bars, 10 µm. **(G)** Percentages of cells showing accumulation of peroxisomes in the cell periphery in F are represented as means ± SD (error bars). Cells (*n* ≥ 20) for each condition in three independent experiments.](JCB_201708122_Fig5){#fig5}

In contrast, when all of the Miro1 variants were knocked down in HeLa/EGFP-SKL cells by *Miro1* siRNA treatment ([Fig. 5 D](#fig5){ref-type="fig"}), the DMF of peroxisomes was significantly reduced to a level similar to that in nocodazole-treated cells ([Fig. 5, C and E](#fig5){ref-type="fig"}; and Videos 3 and 4). To determine which Miro1 variants were responsible for the fast directional movement of peroxisomes, RNAi-resistant forms of mCherry-Miro1 variants, named rescue variants, were reintroduced into Miro1-depleted HeLa/EGFP-SKL cells. A rescue variant mCherry--Miro1-var4 restored the compromised peroxisomal movement and further enhanced the DMF value to ∼24% ([Fig. 5 E](#fig5){ref-type="fig"} and Video 5), a comparable level to that in normal cells expressing mCherry--Miro1-var4 ([Fig. 5 B](#fig5){ref-type="fig"} and Video 2). DMF was similarly rescued by mCherry--Miro1-var2 ([Fig. 5 E](#fig5){ref-type="fig"} and Video 6) but not mCherry--Miro1-var1 ([Fig. 5 E](#fig5){ref-type="fig"}). Collectively, these results suggest that Miro1-var2 and Miro1-var4, both localized to peroxisomes, play a pivotal role in intracellular transport of peroxisomes.

Pex14p, a main component in the peroxisomal protein translocation machinery, was shown to directly interact with microtubules, and the fast peroxisomal movement was not observed in *PEX14*-deficient cells ([@bib5]). Therefore, we verified Miro1 variant--dependent peroxisomal movement in fibroblasts derived from a *PEX14*-deficient patient with Zellweger syndrome ([@bib61]). In normal fibroblasts, HA~2~--Miro1-var4 was colocalized with EGFP-Pex26p in Pex14p-positive peroxisomes and induced the accumulation of peroxisomes at cell peripheries ([Fig. 5 F](#fig5){ref-type="fig"}, a--d, arrowheads; and [Fig. 5 G](#fig5){ref-type="fig"}) as observed in HeLa cells ([Fig. 4 A](#fig4){ref-type="fig"}). In *PEX14*-deficient fibroblasts defective in matrix protein import, HA~2~--Miro1-var4 protein was coincided with peroxisomal membrane remnants labeled with EGFP-Pex26p ([Fig. 5 F](#fig5){ref-type="fig"}, e--h; [Fig. 5 G](#fig5){ref-type="fig"}; Fig. S4 B). Moreover, such membrane remnants were not stained with the markers LC3 and cathepsin D for autophagosomes (Fig. S4 B, a--e) and lysosomes (f--j). These results indicated that the coexpressed HA~2~--Miro1-var4 was translocated to the peroxisomal membrane remnants. However, any accumulation of such remnants to the cell periphery was hardly detectable ([Fig. 5 F](#fig5){ref-type="fig"}, e--h). Collectively, these results suggest that Pex14p is indispensable for Miro1-var4--mediated peroxisomal movement.

Miro1-var4 interacts with TRAK2, a component of the mitochondrial transport complex {#s09}
-----------------------------------------------------------------------------------

TRAK1 and TRAK2 interact with mitochondrial Miro1-var1 and Miro2 and function as adapters to link mitochondrial Miro proteins and molecular motors, kinesins, and dyneins, thus forming the transport machinery complexes in microtubule-dependent mitochondrial trafficking ([@bib9]; [@bib37]; [@bib66]). To investigate whether peroxisome-localized Miro1-var4 interacts with TRAK proteins, HA~2~-Miro1 variants were coexpressed with FLAG-tagged TRAK proteins in HEK cells. Immunoprecipitation with anti-FLAG antibody revealed that HA~2~--Miro1-var4 interacted with FL-TRAK2 as efficiently as HA~2~--Miro1-var1 ([Fig. 6 A](#fig6){ref-type="fig"}). FLAG-TRAK2 was mainly localized in tubular network structures, mitochondria in HeLa cells ([Fig. 6 B](#fig6){ref-type="fig"}, a and e). Notably, a part of FLAG-TRAK2 was merged with coexpressed HA~2~--Miro1-var4 in peroxisomes ([Fig. 6 B](#fig6){ref-type="fig"}, arrowheads). To further assess the interaction of endogenous peroxisomal Miro1 variants with TRAK2, HEK cells transiently expressing HA~2~-TRAK2 was subjected to immunoprecipitation with anti--Miro1-ins1 antibody. The PNS fraction ([Fig. 6 C](#fig6){ref-type="fig"}, lane 2) from the HEK cells was centrifuged at 3,000 *g* to remove the pellet (3K*g* pellet, lane 1), and the resulting supernatant (3K*g* sup, lane 3) was further centrifuged at 100,000 *g* to yield a 100,000-*g* pellet fraction (100K*g* pellet, lane 4). The 100K*g* pellet was enriched in peroxisomes and almost devoid of mitochondria and the cytosol as verified by immunoblotting with antibodies to Pex13p, Tom 20, and LDH ([Fig. 6 C](#fig6){ref-type="fig"}, lanes 1--4). The 100k*g* pellet contained endogenous peroxisomal Miro1-var2 ([Fig. 6 C](#fig6){ref-type="fig"}, lane 5), and a part of HA~2~-TRAK2 associated with light organelles (lanes 1--4). From the 100K*g* pellet fraction, anti--Miro1-ins1 antibody specifically immunoprecipitated endogenous Miro1-var2 together with HA~2~-TRAK2 ([Fig. 6 C](#fig6){ref-type="fig"}, lanes 6 and 7). Furthermore, the interaction between endogenous Miro1-var2 and HA~2~-TRAK2 was also confirmed by immunoprecipitation with anti-HA antibody ([Fig. 6 C](#fig6){ref-type="fig"}, lanes 8 and 9). Collectively, these results suggest that peroxisome-localized Miro1-var2 and Miro1-var4 recruit TRAK2 on peroxisomal membrane to form a transport complex involved in peroxisomal movement like that in mitochondrial trafficking.

![**TRAK2 interacts and colocalizes with Miro1-var4 on peroxisomes. (A)** HEK cells were transfected with *HA~2~--Miro1-var4* or *HA~2~--Miro1-var1* with or without *FLAG-TRAK2* as indicated at the top. At 24 h after transfection, cells were solubilized and subjected to immunoprecipitation with anti-FLAG antibody. Immunoprecipitates (IPs; lanes 5--8) and the input (10%; lanes 1--4) were analyzed by SDS-PAGE and immunoblotting with antibodies as indicated on the left. **(B)** HeLa cells were cotransfected for 24 h with *HA~2~--Miro1-var4* and *FLAG-TRAK2* and immunostained with antibodies to FLAG (a and e; green), HA (b and f; red), and Pex14p (c and g; blue). Merged images were shown (d and h), and the boxed areas were fivefold magnified (e--h). Bars: (a--d) 10 µm; (e--h) 2 µm. Arrowheads indicate colocalization of FLAG-TRAK2 with HA~2~---Miro1-var4 in peroxisomes in the cell periphery region. **(C)** A PNS fraction (lane 2) from HEK cells transiently expressing HA~2~-TRAK2 was centrifuged at 3,000 *g* and separated into supernatant (3K*g* sup; lane 1) and pellet (3K*g* pellet; lane 3) fractions as in [Fig. 2 C](#fig2){ref-type="fig"}. The 3K*g* sup fraction was further centrifuged at 100,000 *g* to yield a cytosol-free pellet fraction (100K*g* pellet; lane 4). The resulting 100K*g* pellet was solubilized and subjected to immunoprecipitation with antisera to Miro1-ins1 (lane 7), HA (lane 9), and their respective preimmune sera (pre-imm.; lanes 6 and 8). Equal-volume aliquots of separated fractions (lanes 1--4) and the immunoprecipitates (lanes 6--9) together with the input of the 100K*g* pellet (5%; lane 5) were analyzed by SDS-PAGE and immunoblotting with antibodies indicated on the left.](JCB_201708122_Fig6){#fig6}

Discussion {#s10}
==========

Intracellular transport of peroxisomes is thought to require transport complexes comprising heterogeneous and distinct components such as motor proteins, adapter proteins, and cytoskeleton, depending on the species ([@bib33]; [@bib43]). In this study, we identified two splicing variants of Miro1 localized to peroxisomes, providing not only the molecular basis for linking peroxisomes and molecular motors for long-distance movement of peroxisomes in mammalian cells but also deeper insight into selective import of TA proteins to peroxisomes and mitochondria.

Depletion of all types of Miro1 variants and reexpression of respective Miro1 variants clearly showed that peroxisomal Miro1 variants are essential components for intracellular transport of peroxisomes ([Fig. 5, D and E](#fig5){ref-type="fig"}). Peroxisomal Miro1 variants most likely transport peroxisomes toward the plus ends of the microtubule network in HeLa cells ([Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}), although authentic Miro1-var1 mediates mitochondrial transport in both the anterograde and retrograde directions in mouse hippocampal neurons ([@bib10]). Considering the findings that proper localization of both peroxisomes and mitochondria to neurites is inhibited by elevation of a microtubule-binding protein tau ([@bib62]) and that Miro1-var4 interacts with TRAK2 as Miro1-var1 does ([Fig. 6 A](#fig6){ref-type="fig"}), peroxisomal transport mediated by peroxisomal Miro1 variants most likely shares molecular machineries with mitochondria. However, peroxisomes may be differently regulated in the initiation of organelle movement. In regard to peroxisomal translocation, it is suggested that Pex14p plays a role in anchoring peroxisomes to microtubules ([@bib5]). Our results suggest that Pex14p indirectly acts upstream of Miro1 variants to evoke peroxisomal movement ([Fig. 5 F](#fig5){ref-type="fig"}), although no interaction between Pex14p and the Miro1-var4--TRAK2 complex was observed in vivo ([Fig. 6 A](#fig6){ref-type="fig"}). Therefore, it is possible that Pex14p is prerequisite for transition from stationary state to the condition competent to initiate peroxisomal motility, thereby allowing peroxisomal Miro1 variants to form the complexes for peroxisomal transport. In addition, it is noteworthy that most recent studies reporting that the interaction between the peroxisomal TA protein ACBD5 and ER-resident VAMP-associated proteins A and B (VAPA and VAPB) mediates tethering of peroxisomes to the ER and restricts peroxisomal motility ([@bib70]; [@bib29]). The liberating step of peroxisomes from the ER could be another determinant to initiate peroxisomal movement, where Pex14p and peroxisomal Miro1 variants might be involved.

Mechanisms underlying the regulation with respect to the direction of peroxisomal movement and intracellular positioning remain undefined. Miro1-var1 and Miro2 interacts with the adapter proteins, TRAK1 and TRAK2, both of which mediate kinesin- and dynein-driven transport of mitochondria in both directions ([@bib6]; [@bib57]; [@bib59]). Bidirectional transport of peroxisomes was observed in axonlike processes of mouse human olfactory neural stem cell lines ([@bib64]) and was shown to be regulated by kinesin and dynein motors in *Drosophila melanogaster* S2 cells ([@bib34]; [@bib2]), implying that peroxisomal Miro1 variants are involved in the bidirectional movement of peroxisomes. However, we do not exclude the possibility that any factor or factors other than peroxisomal Miro1 variants participate in peroxisomal transport because peroxisomes distribute, as in control cells, throughout the cytoplasm in *Miro1-*knockout mouse embryonic fibroblasts ([@bib45]) and Miro1-depleted HeLa cells (Fig. S4 B). Indeed, dynein-based minus end--directed transport of peroxisomes is suggested in mammalian cells ([@bib56]; [@bib13]). Further studies would be required to delineate precise molecular mechanisms involving such transport.

Insertion 1--dependent targeting of Miro1 splicing variants to peroxisomes extends our knowledge of TA protein import in mammals. Generally, targeting information of TA proteins resides in the TMD and a following luminal tail, where peroxisomal TA requires relatively low hydrophobicity and positive charge in the tail ([@bib68], [@bib69]; [@bib11]). We found that the C-terminal region of Miro1-var1 intrinsically targets to mitochondria and that addition of Pex19p binding site--containing insertion 1 consisting of 32 aa in a 53-aa sequence (in Miro1-var4) or 12-aa peptide (in Miro1-var2) upstream of the TMD can alter the destination of Miro1 variants from mitochondria to peroxisomes ([Figs. 1](#fig1){ref-type="fig"} and S2). Importantly, all splicing variants of Miro1 share the same TMD and tail region, indicating that recognition by Pex19p via the cis-acting region is also an important determinant in targeting to the peroxisomal membrane. In regard to peroxisomal targeting of Miro1-var2 and Miro1-var4, the insertion 2 present only in Miro1-var4 enhances peroxisomal import of Miro1-var4, although it is dispensable for mitochondrial localization of Miro1-var3 ([Figs. 1](#fig1){ref-type="fig"} and S2). Despite that Miro1-var4 and Miro1-var2 are similarly recognized by Pex19p in vitro ([Fig. 3, A and C](#fig3){ref-type="fig"}), more efficient peroxisomal import of Miro1-var4 appears to be achieved by conformational change of the C-terminal region in combination with the insertion 2. Furthermore, the peroxisomal Miro1 variants appear to be tightly maintained, with their protein level at much lower than mitochondrial Miro1 variants ([Fig. 2, A and B](#fig2){ref-type="fig"}). Elevation of Miro1-var4 level readily gives rise to accumulation of peroxisomes in the cell periphery ([Fig. 4](#fig4){ref-type="fig"}), which is explained by the finding that a small portion of Miro1-var2 and an undetectable level of Miro1-var4 are present in peroxisomal fractions in HEK cells ([Fig. 2, A and B](#fig2){ref-type="fig"}). Such regulation is most likely accomplished by low efficiency of peroxisomal targeting ([Figs. 1](#fig1){ref-type="fig"} and S2) and a minimum level of mRNA expression (Fig. S1 C). Very recently, [@bib12] reported that exogenously expressed Myc--Miro1-var1 dually localized to mitochondria and peroxisomes in Cos7 cells. This observation is not consistent with our results. Such contradiction might be a result of the use of different cell lines or the difference of expression levels of Miro1.

Peroxisomes play essential roles in many metabolic functions such as decomposition of a harmful substrate, hydrogen peroxide, and β-oxidation of very long chain fatty acids ([@bib65]). Therefore, in analogy to mitochondria, correct transport and intracellular positioning of peroxisomes may be important in polarized cells, especially in neurons. We observed ubiquitous and much fewer levels of mRNA expression of *Miro1-var2* and *Miro1-var4*, respectively, in mouse brains (unpublished data). Interestingly, neuron-specific *Miro1-*knockout mice lacking all splicing variants of Miro1 show that defects in the movement and distribution of mitochondria induce motor neuron disease ([@bib45]). In the *Miro1*-deficient neuron of this mouse, mitochondrial distribution is compromised because of the defect of retrograde mitochondrial transport ([@bib45]). Based on our findings, it is plausible that peroxisomal movement and distribution are also disturbed in Miro1-deficient neurons of *Miro1*-knockout mouse, possibly leading to the pathogenesis of the mouse brain. Deficiency of peroxisome biogenesis causes severe Zellweger spectrum disorders with multiple neurological defects including the impaired neuronal migration in the cerebellum and cerebral cortex ([@bib65]; [@bib4]). Moreover, distribution of peroxisomes to the distal region in primary neurons is inhibited by knockout of *PEX13* ([@bib44]) and overexpression of tau ([@bib62]). Similarly, transport of peroxisomes in axonlike processes of human olfactory neural stem cell lines is impaired by a mutation in *SPAST* encoding a microtubule-severing protein, spatin, in hereditary spastic paraplegia ([@bib1]; [@bib16]). These findings suggest a crucial role of peroxisomal movement and distribution in the progression of neurological dysfunction in peroxisome biogenesis disorders and neurodegenerative diseases.

Materials and methods {#s11}
=====================

Cell culture, DNA transfection, and RNAi {#s12}
----------------------------------------

HeLa cells, HEK cells, human skin fibroblasts from a normal control, and a patient with peroxisome biogenesis disorder with *PEX14* deficiency (K-01; [@bib61]) were cultured in DMEM (Invitrogen) supplemented with 10% FBS at 37°C under 5% CO~2~ and 95% air. CHO-K1 cells were cultured in Ham's F-12 medium supplemented with 10% FBS. DNA was transfected with Lipofectamine 2000 (Invitrogen) for HeLa and HEK cells and Lipofectamine reagent (Invitrogen) for CHO-K1 cells according to the manufacturer's instructions. DNA transfection into fibroblasts was performed by a NEPA21 type II electroporator (Nepagene) at setting of 150 V and 5 ms using a 2-mm gap cuvette. Knockdown of *Miro1* in HeLa cells was conducted by transfection of Stealth RNAi siRNA (Invitrogen) with Lipofectamine 2000 according to the manufacturer's instructions. The sequence of siRNA for human *Miro1* was 5′-UAACCAAAUCGUCGAAGCACAGUCC-3′. Stealth RNAi Negative Control Medium GC Duplex (Invitrogen) was used as a control.

Plasmids {#s13}
--------

All plasmids used in this study were constructed by standard methods and verified by DNA sequencing. Primers used for PCR were shown in Table S1. cDNAs encoding human Miro1, its splicing variants, Miro2, TRAK1, and TRAK2 were obtained by RT-PCR using total RNA from HEK cells. Amplified cDNAs each coding for full-length Miro1 splicing variants, Miro1-var2ΔTMD (residues at 2--624 aa), Miro1-var4ΔTMD (residues at 2--665 aa), and full-length Miro2 were cloned into the BamHI--XhoI sites in a pcDNA3.1Zeo^+^/HA~2~-Ub vector ([@bib48]) by replacing the ubiquitin-encoding fragment, generating pcDNA3.1Zeo-based plasmids encoding N-terminally HA~2~-tagged Miro1 variants and full-length Miro2. cDNA encoding TRAK1 and TRAK2 were likewise cloned into pcDNA3.1Zeo^+^/FLAG-Ub vector and pcDNA3.1Zeo^+^/HA~2~-Ub vector ([@bib48]) at the BamHI--XhoI and BamHI--NotI sites, respectively, generating pcDNA3.1Zeo/FLAG-TRAK1, pcDNA3.1Zeo/FLAG-TRAK2, and pcDNA3.1Zeo/HA~2~-TRAK2. cDNAs encoding Miro1 splicing variants were also ligated into the BamHI--XhoI sites in a modified pcDNA3.1Zeo^+^ vector (Invitrogen) encoding an N-terminal mCherry tag derived from an mCherry-C1 vector (Takara Bio Inc.), generating pcDNA3.1Zeo vector--encoding mCherry-Miro1 variants. The nontagged version of Miro1 variants was generated by cloning cDNAs of full-length Miro1 variants into the BamHI--XhoI sites in a pcDNA3.1Zeo^+^ vector. HA~2~-Miro1 variants each harboring mutations P13V, T18N, L608P, or two KR2S (K648S/R650S in Miro1-var2 and K689S/R691S in Miro1-var4) and siRNA-resistant mutants of mCherry-Miro1 variants in pcDNA3.1Zeo vector were generated by overlapping extension PCR ([@bib27]). To construct FLAG-EGFP--fused C-terminal regions of Miro1 variants, DNA fragments coding for the regions encompassing residues at 574 aa to their respective C terminus were PCR amplified and cloned into the BamHI--XhoI sites of a modified pcDNA3.1Zeo^+^ vector encoding N-terminal FLAG-EGFP tag. Plasmids pcDNAZeo/FLAG-PEX19 ([@bib68]), pcDNAZeo/HA~2~-PEX19 ([@bib39]), pcDNAZeo/HA~2~-PEX26 ([@bib68]), and EGFP-PEX26 ([@bib68]) were also used.

Semiquantitative PCR {#s14}
--------------------

DNA fragments corresponding with those encoding several C-terminal regions of human Miro1 were amplified by RT-PCR using a pair of primers, quantitative PCR (qPCR)-Miro1-Fw and qPCR-Miro1-Rv (Table S1), and total RNA from HeLa cells as a template. Amplified DNA fragments were separated by electrophoresis in 1% agarose gel, stained with ethidium bromide, and visualized with a FAS-II imaging system (Nippon Genetics).

Antibodies {#s15}
----------

Rabbit polyclonal antibodies to C-terminal 19-aa residues of Pex14p ([@bib60]), Pex13p ([@bib41]), Pex3p ([@bib21]), acyl-CoA oxidase ([@bib63]), HA ([@bib49]), LC3 (MBL), cathepsin D (a gift from K. Kato; [@bib46]), and guinea pig anti-Pex14p antibody ([@bib42]) were used. Rabbit antiserum to the insertion 1 in human Miro1-var2 and Miro1-4, termed anti--Miro1-ins1 antibody, was raised by conventional subcutaneous injection of a synthetic 32-aa peptide (EDHYRDRLSRDMGHTDRIENLRKIWVFLKTAF) that had been linked to keyhole limpet hemocyanin ([@bib63]). Rabbit antibody was purified by affinity chromatography using a CL-4B column (GE Healthcare) conjugated to GST-Miro1--insertion 1 encompassing the 32-aa sequence according to the manufacturer's instructions. The following primary antibodies were purchased: rabbit polyclonal antibodies to FLAG (Sigma-Aldrich) and Miro1/2 (Santa Cruz Biotechnology, Inc.), mouse monoclonal antibodies to HA (16B12; Covance), FLAG (Sigma-Aldrich), cytochrome P450 reductase (F-10; Santa Cruz Biotechnology, Inc.), α-tubulin (Abcam), and Tom20 (Santa Cruz Biotechnology, Inc.), and goat anti--lactate dehydrogenase antibody (Rockland).

Immunofluorescence microscopy {#s16}
-----------------------------

Immunostaining of cells was performed as described previously ([@bib47]) using 4% paraformaldehyde for cell fixation and 0.1% Triton X-100 or 25 µg/ml digitonin for permeabilization. Immune complexes were visualized using Alexa Fluor 488-- or 568--labeled goat anti--rabbit or anti--mouse IgG antibody and Alexa Fluor 647--labeled goat anti--guinea pig IgG antibody (Invitrogen). Cells were observed by a confocal laser microscope (LSM510 with Axio Observer.Z1; ZEISS) equipped with a Plan Apochromat 100× 1.4 NA oil immersion objective lens and argon plus dual HeNe lasers at RT. Images were acquired with Zen software (ZEISS) and prepared using Photoshop (CS4; Adobe). In [Figs. 4 C](#fig4){ref-type="fig"} and [5 G](#fig5){ref-type="fig"}, accumulation of peroxisomes at the cell periphery was scored by visually counting the cell showing such morphology.

Live imaging of peroxisomes {#s17}
---------------------------

HeLa cells stably expressing EGFP fused with a peroxisome targeting signal type-1 at its C terminus, termed HeLa/EGFP-SKL cells ([@bib40]), were seeded in 35-mm glass-bottomed dishes at 24 h before assays. A confocal scanning laser microscope (LSM510 with Axio Observer.Z1) equipped with a Plan Apochromat 100× 1.4 NA oil immersion objective lens and a thermostatic stage was kept at 37°C and 5% CO~2~ was used during the course of the live-imaging experiments. Excitation illumination was from an argon ion laser (488 nm). A total of 300 time-lapse images were acquired for 5 min and focused on one cell (one picture per second) and analyzed with MetaMorph software (Molecular Devices). The total number of peroxisomes in a cell in the first frame and the number of peroxisomes showing movement with a velocity \>0.5 µm/s and in distance \>2 µm were monitored. We defined an index, DMF, to describe population of peroxisomes with fast and long-distance movement as follows: DMF = (number of peroxisomes with directional movement in 5 min)/(total number of peroxisomes).

Subcellular fractionation {#s18}
-------------------------

Isopycnic ultracentrifugation using iodixanol gradient was performed as described previously ([@bib28]), except using HEK cells and a 19--30% linear gradient of iodixanol (OptiPrep; Sigma-Aldrich). In brief, the PNS of HEK cells (∼10^7^ cells) was prepared with a Potter-Elvehjem homogenizer in buffer H (20 mM Hepes-KOH, pH 7.4, 0.25 M sucrose, 1 mM DTT, and complete protease inhibitor cocktail \[Roche\]). A 19--30% linear iodixanol gradient was created in a 14 × 89 mm centrifuge tube (Beckman Coulter) by a Gradient Master (Biocomp) according to the manufacturer's protocol. The PNS fraction was suspended in 35% iodixanol solution and was placed beneath the linear gradient and centrifuged at 100,000 *g* for 90 min at 4°C in a SW41Ti rotor (Beckman Coulter). The gradient was collected into 12 fractions. Organelles in each fraction were pelleted down for immunoblot analysis by diluting with an equal volume of buffer H and centrifugation at 100,000 *g* for 20 min at 4°C.

To analyze the topology of peroxisomal Miro1 variants, the PNS fraction of HEK cells was centrifuged at 3,000 *g* for 10 min at 4°C to yield a 3,000-*g* supernatant (3K*g* sup) fraction almost excluding mitochondria. The 3,000-*g* supernatant fraction was treated with 1 M NaCl or 0.1 M Na~2~CO~3~ for alkaline extraction ([@bib19]) on ice for 30 min and separated into soluble and membrane fractions by ultracentrifugation at 100,000 *g* for 30 min at 4°C. A protease protection assay was then performed by incubating the 3,000-*g* supernatant fraction with 100 µg/ml trypsin for 30 min on ice in the absence or presence of 0.1% Triton X-100. For immunoprecipitation of endogenous Miro1 variants in peroxisomes, the PNS fraction of HEK cells was separated into supernatant (3K*g* sup) and pellet (3K*g* pellet) fractions by centrifugation at 3,000 *g* for 10 min at 4°C as described above. The 3K*g* sup fraction was further centrifuged at 100,000 *g* for 30 min at 4°C to yield a 100,000-*g* pellet (100K*g* pellet) fraction. Separation of cytosolic and organelle fractions from CHO-K1 cells was performed by incubating the harvested cells for 10 min on ice with buffer H containing 100 µg/ml digitonin followed by ultracentrifugation at 100,000 *g* for 30 min at 4°C as described previously ([@bib35]).

Cell-free synthesis of proteins {#s19}
-------------------------------

A quick-coupled transcription/translation system (T~N~T T7; Promega) was used for in vitro transcription/translation reactions in RRL according to the manufacturer's instructions. Miro1 variants and Pex26p were synthesized in the reaction mixtures supplemented with RRL-synthesized Pex19p to synthesize proteins in the presence Pex19p at 10% of the final reaction volume as described previously ([@bib68]). After centrifugation at 100,000 *g* for 30 min at 4°C, the supernatant was used for the immunoprecipitation.

In vitro import assay using semiintact cells {#s20}
--------------------------------------------

HeLa cells were semipermeabilized as described previously ([@bib38]). In brief, cells cultured on 18-mm glass coverslips were incubated for 10 min on ice with 5% BSA in buffer S (0.25 M sucrose, 25 mM Hepes-KOH, pH 7.4, 2.5 mM EGTA, 2.5 mM magnesium acetate, 50 mM KCl, and 1 mM DTT). After washing with ice-cold buffer S, cells were incubated with 50 µg/ml digitonin in buffer S for 5 min at RT, washed three times with ice-cold buffer S, and incubated in buffer S for 30 min on ice. PNS fractions of HeLa cells expressing Pex19p and Miro1 variants were prepared as HEK cells using buffer S, and the cytosolic fractions were isolated by ultracentrifugation at 100,000 *g* for 30 min at 4°C. Semiintact HeLa cells were incubated for 1 h at 26°C with the cytosolic fractions. After extensive wash with buffer S, cells were fixed for immunofluorescence microscopy or subjected to alkaline extraction as described in the Subcellular fractionation section.

Immunoprecipitation {#s21}
-------------------

For immunoprecipitation from cell lysates, cells expressing FLAG-tagged Miro1 variants or TRAK2 were lysed in buffer L (40 mM Hepes-KOH, pH 7.4, 0.15 M NaCl, 0.5% Triton X-100, 1 mM EDTA, 1 mM DTT, and the protease inhibitor cocktail \[1 mM PMSF and 10 µg/ml each of aprotinin, leupeptin, and pepstatin\]). Cell lysates were centrifuged at 20,000 *g* for 10 min at 4°C to remove insoluble cell debris. Resulting supernatants were mixed with anti-FLAG antibody--conjugated agarose beads (Sigma-Aldrich) and incubated at 4°C for 1 h. After washing with buffer L, proteins bound to the beads were eluted with buffer L containing 100 µg/ml FLAG peptide (Sigma-Aldrich) and analyzed by SDS-PAGE and immunoblotting. For immunoprecipitation of endogenous Miro1 variants in peroxisomes, a 100,000-*g* pellet (100K*g* pellet) fraction from PNS fraction of HEK cells transiently expressing HA~2~-TRAK2 was lysed in buffer L. After centrifugation at 20,000 *g* for 10 min at 4°C, resulting supernatants were incubated with antibody to Miro1-ins1 or HA in buffer L for 4 h at 4°C. Antibody--antigen complexes were recovered by incubating for 1 h at 4°C with Protein A Sepharose CL-4B (GE Healthcare) and eluted with Laemmli sample buffer. For immunoprecipitation using cell-free synthesized proteins, in vitro translation products were incubated with anti-FLAG antibody--conjugated agarose beads after dilution with buffer C (0.1% CHAPS, 20 mM Hepes-KOH, pH 7.4, 0.15 M KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, and protease inhibitor cocktail). After washing with buffer C, immunoprecipitates were analyzed by SDS-PAGE and immunoblotting.

Statistical analysis {#s22}
--------------------

Quantitative data were represented as means ± SD from at least three independent experiments. Statistical significance was determined using a two-tailed unpaired Student's *t* test or one-way ANOVA with Dunnett's post hoc test. P-values of \<0.05 were considered statistically significant.

Online supplemental material {#s23}
----------------------------

Fig. S1 shows information on DNA and protein sequences of human Miro-1 variants and mRNA level of Miro1 variants in HEK cells. Fig. S2 shows peroxisomal localization of FL-EGFP-MVC variants and membrane topology of Miro1-var4. Fig. S3 shows that both L608P and KR2S mutations inhibit peroxisomal localization of Miro1 variants. Fig. S4 shows localization of mCherry-Miro1 variants in normal cells, localization of Miro1-var4 in *PEX14*-deficient fibroblasts, and morphology of peroxisomes and mitochondria in Miro1-knockdown cells. Video 1 shows peroxisomal movement in control cells. Video 2 shows that Miro1-var4 expression enhances peroxisomal movement. Video 3 shows peroxisomal movement in control siRNA-treated cells. Video 4 shows decreased peroxisomal movement in Miro1-knockdown cells. Videos 5 and 6 show that the lowered peroxisomal movement in Miro1-knockdown cells was restored by expression of Miro1-var4 and Miro1-var2, respectively. Table S1 shows the primers and the sequences used in this study.
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